Edgar Filing: QIAGEN NV - Form 6-K

QIAGEN NV Form 6-K November 26, 2008 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2008

QIAGEN N.V.

Spoorstraat 50

5911 KJ Venlo

The Netherlands

Edgar Filing: QIAGEN NV - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F "
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes " No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: QIAGEN NV - Form 6-K

Table of Contents

QIAGEN N.V.

Form 6-K

TABLE OF CONTENTS

Item Other Information	Page 3
Signatures	4
Exhibit Index	5

2

OTHER INFORMATION

For the three and nine month periods ended September 30, 2008, QIAGEN N.V. prepared its quarterly report under United States Generally Accepted Accounting Principles (US GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

By: /s/ Roland Sackers Roland Sackers Chief Financial Officer

Date: November 25, 2008

4

EXHIBIT INDEX

Exhibit No. Exhibit

99.1 U.S. GAAP Quarterly Report for the Period Ended September 30, 2008

5

Exhibit 99.1

QIAGEN N.V.

U.S. GAAP QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, $2008\,$

TABLE OF CONTENTS

Financial Information	
Consolidated Financial Statements	
Condensed Consolidated Balance Sheets as of September 30, 2008 (unaudited) and December 31, 2007	2
Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2008 and 2007	4
Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2008 and 2007	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Operating and Financial Review and Prospects	27
Quantitative and Qualitative Disclosures About Market Risk	34
Recent Authoritative Pronouncements	34
Application of Critical Accounting Policies, Judgments and Estimates	34
Contractual Obligations	34
Legal Proceedings	35
Risk Factors	35

1

September 30, 2008 U.S. GAAP Quarterly Report

QIAGEN N.V.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value and share data)

	September 30, 2008 (unaudited)		December 31, 2007	
Assets				
Current Assets:				
Cash and cash equivalents	\$	326,034	\$	347,320
Marketable securities				2,313
Accounts receivable, net of allowance for doubtful accounts of \$3,061 and \$3,344 in 2008 and 2007,				
respectively		151,820		136,707
Notes receivable		3,271		5,139
Income taxes receivable		30,095		10,696
Inventories, net		113,733		88,346
Prepaid expenses and other		38,746		33,693
Deferred income taxes		44,357		23,732
Total current assets		708,056		647,946
Long-Term Assets:				
Property, plant and equipment, net		284,216		283,491
Goodwill		1,134,327		1,107,882
Intangible assets, net of accumulated amortization of \$115,001 and \$65,129 in 2008 and 2007, respectively		633,173		639,107
Deferred income taxes		77,826		72,128
Other assets		35,278		24,620
Total long-term assets		2,164,820		2,127,228
Total assets	\$	2,872,876	\$	2,775,174

The accompanying notes are an integral part of these condensed consolidated financial statements.

September 30, 2008 U.S. GAAP Quarterly Report

2

QIAGEN N.V.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value and share data)

Liabilities and Shareholders Equity		September 30, 2008 (unaudited)		ecember 31, 2007
Current Liabilities:				
Accounts payable	\$	41,158	\$	40,379
Accrued and other liabilities (of which \$10,018 and \$6,410 due to related parties in 2008 and 2007,				
respectively, see Note 17)		110,421		104,224
Income taxes payable		27,453		13,456
Current portion of long-term debt		25,000		
Current portion of capital lease obligations		3,011		2,769
Deferred income taxes		7,862		4,903
		•		
Total current liabilities		214,905		165,731
Total Carron Incomines		211,500		105,751
Long Town Lightities				
Long-Term Liabilities: Long-term debt (of which \$450,000 in 2008 and 2007 due to related parties, see Note 8)		925,000		950,000
Capital lease obligations, net of current portion		30,593		33,017
Deferred income taxes				
Other		237,110 7,132		225,893 8,405
Other		1,132		8,403
		4 400 00		
Total long-term liabilities		1,199,835		1,217,315
Minority interest in consolidated subsidiary		376		553
Commitments and Contingencies (Note 15)				
Communents and Condingencies (Note 13)				
Shareholders Equity:				
Preference shares, 0.01 EUR par value, authorized 450,000,000 shares, no shares issued and outstanding				
Financing preference shares, 0.01 EUR par value, authorized 40,000,000 shares, no shares issued and				
outstanding				
Common Shares, 0.01 EUR par value, authorized 410,000,000 shares, issued and outstanding 197,283,486 and				
195,335,076 shares in 2008 and 2007, respectively		2,205		2,175
Additional paid-in capital		955,769		925,597
Retained earnings		453,129		388,779
Accumulated other comprehensive income		46,657		75,024
•		-		•
Total shareholders equity		1,457,760		1,391,575
1. Chail Shake Political Control of the Control of		2,127,700		1,071,070
Total liabilities and shougholdons, equity	¢	2 972 977	¢	2 775 174
Total liabilities and shareholders equity	\$	2,872,876	Ф	2,775,174

The accompanying notes are an integral part of these condensed consolidated financial statements.

September 30, 2008 U.S. GAAP Quarterly Report

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

	Three Months Ended September 2008 2007					
	(unaudited			/		
Net sales	\$	230,800	\$	176,632		
Cost of sales		64,688		50,695		
Cost of sales acquisition related		396		1,343		
Cost of sales acquisition related intangible amortization		12,777		8,406		
Gross profit		152,939		116,188		
•						
Operating Expenses:						
Research and development		24,073		17,870		
Sales and marketing		55,972		45,162		
General and administrative		21,142		21,470		
Purchased in-process research and development		830		25,900		
Acquisition, integration and related costs		8,554		4,546		
Acquisition related intangible amortization		4,018		2,951		
Relocation and restructuring costs		172				
C						
Total operating expenses		114,761		117,899		
Income (loss) from operations		38,178		(1,711)		
		, -		()-)		
Other Income (Expense):						
Interest income		2,095		5,414		
Interest expense		(9,194)		(10,742)		
Other (expense) income, net		(3,233)		1,084		
other (expense) meome, net		(3,233)		1,001		
Total other expense		(10,332)		(4,244)		
Income (loss) before provision for income taxes and minority interest		27,846		(5,955)		
Provision for income taxes		6,679		1,380		
Minority interest expense (income)		376		(7)		
7				()		
Net income (loss)	\$	20,791	\$	(7,328)		
Basic net income (loss) per Common Share	\$	0.11	\$	(0.04)		
Diluted net income (loss) per Common Share	\$	0.10	\$	(0.04)		

The accompanying notes are an integral part of these condensed consolidated financial statements.

September 30, 2008 U.S. GAAP Quarterly Report

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

	Nine Months Ended September 30, 2008 2007			
	(unaudited)			
Net sales	\$	655,794	\$	439,550
Cost of sales		177,607		131,201
Cost of sales acquisition related		396		1,343
Cost of sales acquisition related intangible amortization		35,552		12,256
Gross profit		442,239		294,750
•		ĺ		
Operating Expenses:				
Research and development		69,281		42,091
Sales and marketing		167,746		108,460
General and administrative		61,345		48,760
Purchased in-process research and development		830		25,900
Acquisition, integration and related costs		26,621		6,582
Acquisition related intangible amortization		10,484		4,357
Relocation and restructuring costs		706		478
Total operating expenses		337,013		236,628
Income from operations		105,226		58,122
		,		
Other Income (Expense):				
Interest income		7,391		15,840
Interest expense		(28,832)		(20,356)
Other (expense) income, net		(672)		1,965
Total other expense		(22,113)		(2,551)
Income before provision for income taxes and minority interest		83,113		55,571
Provision for income taxes		18,272		20,456
Minority interest expense (income)		491		(7)
Net income	\$	64,350	\$	35,122
Basic net income per common share	\$	0.33	\$	0.22
Diluted net income per common share	\$	0.31	\$	0.21

The accompanying notes are an integral part of these condensed consolidated financial statements.

September 30, 2008 U.S. GAAP Quarterly Report

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Nine	Months End 2008 (unau	led Sep	otember 30, 2007
Cash Flows From Operating Activities:		(,	
Net income	\$	64,350	\$	35,122
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses				
acquired:				
Depreciation and amortization		32,693		21,295
Acquisition-related intangible amortization		46,036		16,613
Purchased in-process research and development		830		25,900
Non-cash charges for impairment and sale of inventories revalued at the date of acquisition		4,396		1,343
Share-based compensation expense		6,651		3,990
Excess tax benefits from share-based compensation		(5,860)		(9,368)
Gain on sale of marketable securities		(780)		
Other non-cash items		105		1,208
Net changes in operating assets and liabilities:				
Accounts receivable		(14,209)		(13,681)
Inventories		(33,026)		(7,209)
Other operating assets and liabilities		(16,712)		(12,517)
Net cash provided by operating activities		84,474		62,696
		,		
Cash Flows From Investing Activities:				
Purchases of property, plant and equipment		(26,885)		(23,837)
Proceeds from sale of equipment				